We are live on ! Find out more
SNOA icon

Sonoma Pharmaceuticals
SNOA

17 hedge funds and large institutions have $144K invested in Sonoma Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 1

300% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 1

6% more funds holding

Funds holding: 16 → 17 (+1)

2.5% less ownership

Funds ownership: 6.4% → 3.9% (-2.5%)

64% less capital invested

Capital invested by funds: $396K → $144K (-$253K)

Holders
17
Holders Change
+1
Holders Change %
+6.25%
% of All Funds
0.21%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
4
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Geode Capital Management
Geode Capital Management
Massachusetts
+$11.8K
2
Morgan Stanley
Morgan Stanley
New York
+$5.85K
3
Citigroup
Citigroup
New York
+$4.17K
4
TRCT
Tower Research Capital (TRC)
New York
+$2.47K
5
JP Morgan Chase
JP Morgan Chase
New York
+$6

Top Sellers

Rank Fund Capital Flow
1
DS
DRW Securities
Illinois
-$143K
2
Bank of America
Bank of America
North Carolina
-$65
Name Holding Trade Value Shares
Change 		Change in
Stake
Geode Capital Management
1
Geode Capital Management
Massachusetts
$42.5K +$11.8K +4,033 +25%
VCM
2
Vanguard Capital Management
Pennsylvania
$40K +$54.9K +18,787 New
DS
3
DRW Securities
Illinois
$25.6K -$143K -48,962 -80%
MCWS
4
McKinley Carter Wealth Services
West Virginia
$23.8K – – –
Morgan Stanley
5
Morgan Stanley
New York
$4.27K +$5.85K +2,000 +50,000%
Citigroup
6
Citigroup
New York
$3.04K +$4.17K +1,425 New
TRCT
7
Tower Research Capital (TRC)
New York
$2.62K +$2.47K +846 +220%
Osaic Holdings
8
Osaic Holdings
Arizona
$1.06K – – –
JP Morgan Chase
9
JP Morgan Chase
New York
$255 +$6 +2 +2%
BlackRock
10
BlackRock
New York
$241 – – –
VFT
11
Vanguard Fiduciary Trust
Pennsylvania
$213 +$292 +100 New
US Bancorp
12
US Bancorp
Minnesota
$53 – – –
UBS Group
13
UBS Group
Switzerland
$13 – – –
QWM
14
Quaker Wealth Management
New Jersey
$7 – – –
Carson Wealth (CWM LLC)
15
Carson Wealth (CWM LLC)
Nebraska
$2 – – –
DB
16
Danske Bank
Denmark
$2 – – –
CIAM
17
Caitong International Asset Management
Hong Kong
$2 +$3 +1 New
Bank of America
18
Bank of America
North Carolina
– -$65 -18 Closed

SNOA Hedge Fund Activity: Q1 2026 in Review

17 of the 8,130 institutional investors tracked by Wall St. Rank reported a position in Sonoma Pharmaceuticals (SNOA) for Q1 2026, worth a combined $144K — down 64% from $396K a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new SNOA positions and 1 closed out — a net gain of 3 holders — while 4 added to existing stakes and 1 trimmed.

The largest buyer was Geode Capital Management, adding an estimated $11.8K. The largest seller was DRW Securities, cutting an estimated $143K.

  • 17 institutional investors held Sonoma Pharmaceuticals (SNOA) as of Q1 2026, up from 16 in Q4 2025.
  • Funds reported $144K of Sonoma Pharmaceuticals stock for Q1 2026, down 64% quarter-over-quarter.
  • 4 funds opened new Sonoma Pharmaceuticals positions in Q1 2026 and 1 closed out, a net change of +3 holders.
  • The largest Sonoma Pharmaceuticals buyer in Q1 2026 was Geode Capital Management, an estimated $11.8K added.
  • The largest Sonoma Pharmaceuticals seller in Q1 2026 was DRW Securities, an estimated $143K sold.

Based on aggregated 13F filings for Q1 2026.